Skip to main content
PMC home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1995 Mar;4(3):405–415. doi: 10.1002/pro.5560040307

Conformationally constrained analogs of protein kinase inhibitor (6-22)amide: effect of turn structures in the center of the peptide on inhibition of cAMP-dependent protein kinase.

D B Glass 1, J Trewhella 1, R D Mitchell 1, D A Walsh 1
PMCID: PMC2143090  PMID: 7795524

Abstract

The high-affinity interaction between protein kinase inhibitor (PKI)(6-22)amide(Thr6-Tyr-Ala-Asp-Phe-Ile-Ala-Ser-Gly-Arg-Thr-Gly- Arg-Arg-Asn- Ala-Ile22-NH2) and the catalytic subunit of cAMP-dependent protein kinase requires both the N-terminal Thr6 to Ile11 sequence of the inhibitor peptide and its C-terminal pseudosubstrate site comprised of Arg15 to Ile22. Small angle X-ray scattering data indicate that PKI(6-22)amide has a compact, rather than extended, structure in solution (Reed J et al., 1989, Biochem J 264:371-380). CD spectroscopic analysis of the PKI peptide led to the suggestion that a beta-turn structure might be located in the -Ala12-Ser-Gly-Arg15-connecting sequence in the middle of the molecule (Reed J, Kinzel V, Cheng HC, Walsh DA, 1987, Biochemistry 26:7641-7647). To investigate this possibility further, conformationally constrained and flexible analogs of PKI(6-22)amide were synthesized and used to study the structure-function relationships of this central portion of the inhibitor. (Des12-14)PKI(6-22) amide exhibited over a 200-fold loss in inhibitory activity. Replacement of the omitted -Ala12-Ser-Gly14-sequence with aminocaprylic acid yielded an analog that regained more than 90% of the lost binding energy. The D-alanine14 PKI analog was as potent as the parent peptide, whereas the beta-alanine14 and the sarcosine14 analogs were only 10-fold less active. Several peptides that promoted a beta-turn structure at residues 12-15 showed about 200-fold decreases in inhibitory activity. Two constrained analogs that could not assume a beta-turn conformation were only 30-fold less potent than PKI(6-22)amide. Thus, the structure of the central connecting portion of the PKI peptide, encompassing residues 12-15, greatly influences its ability to effectively bind to and inhibit the catalytic subunit. We conclude, however, that a formal beta-turn at this position is not required and is actually detrimental for a high-affinity interaction of PKI(6-22)amide with the enzyme. These results are interpreted in light of the Fourier-transform infrared spectra of the peptide analogs and the crystal structure of the peptide bound at the active site of the protein kinase (Knighton DR et al., 1991b, Science 253:414-420).

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Byler D. M., Susi H. Examination of the secondary structure of proteins by deconvolved FTIR spectra. Biopolymers. 1986 Mar;25(3):469–487. doi: 10.1002/bip.360250307. [DOI] [PubMed] [Google Scholar]
  2. Cheng H. C., Kemp B. E., Pearson R. B., Smith A. J., Misconi L., Van Patten S. M., Walsh D. A. A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase. J Biol Chem. 1986 Jan 25;261(3):989–992. [PubMed] [Google Scholar]
  3. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  4. Chou P. Y., Fasman G. D. Empirical predictions of protein conformation. Annu Rev Biochem. 1978;47:251–276. doi: 10.1146/annurev.bi.47.070178.001343. [DOI] [PubMed] [Google Scholar]
  5. Crisma M., Fasman G. D., Balaram H., Balaram P. Peptide models for beta-turns. A circular dichroism study. Int J Pept Protein Res. 1984 Apr;23(4):411–419. [PubMed] [Google Scholar]
  6. Gibbs C. S., Zoller M. J. Identification of electrostatic interactions that determine the phosphorylation site specificity of the cAMP-dependent protein kinase. Biochemistry. 1991 Jun 4;30(22):5329–5334. doi: 10.1021/bi00236a001. [DOI] [PubMed] [Google Scholar]
  7. Glass D. B., Cheng H. C., Mende-Mueller L., Reed J., Walsh D. A. Primary structural determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein. J Biol Chem. 1989 May 25;264(15):8802–8810. [PubMed] [Google Scholar]
  8. Glass D. B., Lundquist L. J., Katz B. M., Walsh D. A. Protein kinase inhibitor-(6-22)-amide peptide analogs with standard and nonstandard amino acid substitutions for phenylalanine 10. Inhibition of cAMP-dependent protein kinase. J Biol Chem. 1989 Aug 25;264(24):14579–14584. [PubMed] [Google Scholar]
  9. Katz B. M., Lundquist L. J., Walsh D. A., Glass D. B. Synthesis, characterization and inhibitory activities of (4-N3[3,5-3H]Phe10)PKI(6-22)amide and its precursors: photoaffinity labeling peptides for the active site of cyclic AMP-dependent protein kinase. Int J Pept Protein Res. 1989 Jun;33(6):439–445. doi: 10.1111/j.1399-3011.1989.tb00220.x. [DOI] [PubMed] [Google Scholar]
  10. Knighton D. R., Bell S. M., Zheng J., Ten Eyck L. F., Xuong N. H., Taylor S. S., Sowadski J. M. 2.0 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with a peptide inhibitor and detergent. Acta Crystallogr D Biol Crystallogr. 1993 May 1;49(Pt 3):357–361. doi: 10.1107/S0907444993000502. [DOI] [PubMed] [Google Scholar]
  11. Knighton D. R., Zheng J. H., Ten Eyck L. F., Ashford V. A., Xuong N. H., Taylor S. S., Sowadski J. M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 1991 Jul 26;253(5018):407–414. doi: 10.1126/science.1862342. [DOI] [PubMed] [Google Scholar]
  12. Knighton D. R., Zheng J. H., Ten Eyck L. F., Xuong N. H., Taylor S. S., Sowadski J. M. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 1991 Jul 26;253(5018):414–420. doi: 10.1126/science.1862343. [DOI] [PubMed] [Google Scholar]
  13. Prasad B. V., Balaram P. The stereochemistry of peptides containing alpha-aminoisobutyric acid. CRC Crit Rev Biochem. 1984;16(4):307–348. doi: 10.3109/10409238409108718. [DOI] [PubMed] [Google Scholar]
  14. Reed J., De Ropp J. S., Trewhella J., Glass D. B., Liddle W. K., Bradbury E. M., Kinzel V., Walsh D. A. Conformational analysis of PKI(5-22)amide, the active inhibitory fragment of the inhibitor protein of the cyclic AMP-dependent protein kinase. Biochem J. 1989 Dec 1;264(2):371–380. doi: 10.1042/bj2640371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Reed J., Kinzel V., Cheng H. C., Walsh D. A. Circular dichroic investigations of secondary structure in synthetic peptide inhibitors of cAMP-dependent protein kinase: a model for inhibitory potential. Biochemistry. 1987 Dec 1;26(24):7641–7647. doi: 10.1021/bi00398a017. [DOI] [PubMed] [Google Scholar]
  16. Rose G. D., Gierasch L. M., Smith J. A. Turns in peptides and proteins. Adv Protein Chem. 1985;37:1–109. doi: 10.1016/s0065-3233(08)60063-7. [DOI] [PubMed] [Google Scholar]
  17. Rosevear P. R., Fry D. C., Mildvan A. S., Doughty M., O'Brian C., Kaiser E. T. NMR studies of the backbone protons and secondary structure of pentapeptide and heptapeptide substrates bound to bovine heart protein kinase. Biochemistry. 1984 Jul 3;23(14):3161–3173. doi: 10.1021/bi00309a009. [DOI] [PubMed] [Google Scholar]
  18. Scott J. D., Glaccum M. B., Fischer E. H., Krebs E. G. Primary-structure requirements for inhibition by the heat-stable inhibitor of the cAMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1613–1616. doi: 10.1073/pnas.83.6.1613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Showers M. O., Maurer R. A. A cloned bovine cDNA encodes an alternate form of the catalytic subunit of cAMP-dependent protein kinase. J Biol Chem. 1986 Dec 15;261(35):16288–16291. [PubMed] [Google Scholar]
  20. Smith J. A., Pease L. G. Reverse turns in peptides and proteins. CRC Crit Rev Biochem. 1980;8(4):315–399. doi: 10.3109/10409238009105470. [DOI] [PubMed] [Google Scholar]
  21. Trewhella J., Liddle W. K., Heidorn D. B., Strynadka N. Calmodulin and troponin C structures studied by Fourier transform infrared spectroscopy: effects of Ca2+ and Mg2+ binding. Biochemistry. 1989 Feb 7;28(3):1294–1301. doi: 10.1021/bi00429a052. [DOI] [PubMed] [Google Scholar]
  22. Van Patten S. M., Howard P., Walsh D. A., Maurer R. A. The alpha- and beta-isoforms of the inhibitor protein of the 3',5'-cyclic adenosine monophosphate-dependent protein kinase: characteristics and tissue- and developmental-specific expression. Mol Endocrinol. 1992 Dec;6(12):2114–2122. doi: 10.1210/mend.6.12.1491692. [DOI] [PubMed] [Google Scholar]
  23. Walsh D. A., Glass D. B. Utilization of the inhibitor protein of adenosine cyclic monophosphate-dependent protein kinase, and peptides derived from it, as tools to study adenosine cyclic monophosphate-mediated cellular processes. Methods Enzymol. 1991;201:304–316. doi: 10.1016/0076-6879(91)01027-y. [DOI] [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES